Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1999-1-29
pubmed:abstractText
In order to determine the possible correlation of specific immune responses with protection against mortality and ocular disease following ocular herpes simplex virus type 1 (HSV-1) challenge, BALB/c mice were vaccinated with different doses and regimens of baculovirus-expressed gD. Neutralizing antibody, virus titres in the eyes, corneal scarring, and survival were measured. In addition, infiltration into the cornea of CD4+ T cells and cells containing the lymphokines interleukin-2 (IL-2), IL-4, IL-6 and tumour necrosis factor-alpha (TNF-alpha) were monitored on days 3, 7, 10, 14 and 21 post-challenge by immunocytochemistry. The vaccination regimens used induced varying degrees of immune responses and protection upon ocular challenge with HSV-1. Our results suggest that neutralizing antibody was the most important immune response in protecting mice against lethal ocular challenge and corneal scarring. TNF-alpha and IL-2 were not crucial in terms of survival and corneal scarring, since gD1 (one vaccination with 1 microg of gD) and gD0.1 (one vaccination with 0.1 microg of gD), both of which provided high levels of protection, showed no TNF-alpha or IL-2 expression. However, TNF-alpha and IL-2 were crucial in terms of virus clearance from the eyes, since gD3 (three vaccinations with 1 microg of gD), which had less virus in their eyes, had high numbers of TNF-alpha and IL-2 infiltrates. Finally, mock-vaccinated mice were not protected from death and corneal disease following HSV-1 challenge. Eyes of mock-vaccinated mice had little or no TNF-alpha or IL-2 responses and the strongest IL-4 and IL-6 responses.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-1357034, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-1571022, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-1703559, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-178617, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-187060, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-1934628, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-2156001, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-2170289, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-2419430, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-2572669, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-2848928, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-3030656, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-6443690, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-7495514, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-7511551, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-7535865, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-7549333, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-7561696, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-7722330, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-7775113, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-7931062, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-7946039, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-7983727, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-8021510, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-8138996, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-8228262, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-8609495, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-8764032, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-8862430, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-8893001, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-8895836, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-8896488, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-8952229, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-9021916, http://linkedlifedata.com/resource/pubmed/commentcorrection/9824497-988644
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0019-2805
pubmed:author
pubmed:issnType
Print
pubmed:volume
95
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
352-9
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1998
pubmed:articleTitle
The role of neutralizing antibody and T-helper subtypes in protection and pathogenesis of vaccinated mice following ocular HSV-1 challenge.
pubmed:affiliation
Ophthalmology Research, Cedars-Sinai Research Institute, Los Angeles, CA; Department of Ophthalmology, UCLA School of Medicine, Los Angeles, CA 90048, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.